135 related articles for article (PubMed ID: 30768860)
41. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults.
Song Y; Chang M; Suzuki A; Frost RJ; Kelly A; LaCreta F; Frost C
Clin Ther; 2016 Jul; 38(7):1674-1685.e1. PubMed ID: 27292282
[TBL] [Abstract][Full Text] [Related]
43. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
44. Effect of food on the bioavailability of palbociclib.
Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
[TBL] [Abstract][Full Text] [Related]
46. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
[TBL] [Abstract][Full Text] [Related]
47. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
[TBL] [Abstract][Full Text] [Related]
48. Effect of food on the oral bioavailability of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide fixed dose combination tablets in healthy subjects.
Sunkara G; Jiang X; Reynolds C; Serra D; Zhang Y; Ligueros-Saylan M; Ayalasomayajula S; Winter S; Jarugula V
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):487-92. PubMed ID: 27129123
[TBL] [Abstract][Full Text] [Related]
49. Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy.
Patel CG; Rangachari L; Patti M; Griffin C; Shou Y; Venkatakrishnan K
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):637-646. PubMed ID: 30168905
[TBL] [Abstract][Full Text] [Related]
50. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
Guivarc'h PH; Vachon MG; Fordyce D
Clin Ther; 2004 Sep; 26(9):1456-69. PubMed ID: 15531008
[TBL] [Abstract][Full Text] [Related]
51. Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist.
Katsube T; Wajima T; Fukuhara T; Kano T
Clin Ther; 2019 Sep; 41(9):1747-1754.e2. PubMed ID: 31303281
[TBL] [Abstract][Full Text] [Related]
52. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
[TBL] [Abstract][Full Text] [Related]
53. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
54. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects.
Musib L; Choo E; Deng Y; Eppler S; Rooney I; Chan IT; Dresser MJ
Mol Pharm; 2013 Nov; 10(11):4046-54. PubMed ID: 24010577
[TBL] [Abstract][Full Text] [Related]
55. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
57. Filgotinib: A Clinical Pharmacology Review.
Namour F; Anderson K; Nelson C; Tasset C
Clin Pharmacokinet; 2022 Jun; 61(6):819-832. PubMed ID: 35637376
[TBL] [Abstract][Full Text] [Related]
58. Effect of Food on the Pharmacokinetics of Quizartinib.
Li J; Holmes M; Kankam M; Trone D; Mendell J; Gammon G
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):277-286. PubMed ID: 31916418
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.
Yamazaki T; Desai A; Goldwater R; Han D; Howieson C; Akhtar S; Kowalski D; Lademacher C; Pearlman H; Rammelsberg D; Townsend R
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):54-65. PubMed ID: 27273149
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers.
Li L; Xiang YX; Yang GP; Zhang XF; Yang XY; Yang S; Huang J
Invest New Drugs; 2021 Jun; 39(3):796-802. PubMed ID: 33420642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]